|
Golkonda Alumin.
|
513309 |
07-Oct-26 |
Quarterly Results
Golkonda Aluminium Extrusions Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/10/2026 ,inter alia, to consider and approve Pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015 we hereby inform you that a meeting of Board of Directors of the Company will be held on Wednesday 07th October, 2026 at the Registered Office of the Company at 1003, 10th Floor, Vikram Tower, Rajendra place New Delhi - 110008 with respect to following: 1. To consider and approve the Unaudited (Standalone) Financial Results of the Company for the Quarter and half year ended on 30th September, 2026. This is also to inform that the Trading Window of the Company has been closed from 01st October, 2026 and will remain closed till the completion of 48 hours after the declaration of unaudited Financial Results of the Company for the quarter and half year ended on 30th September, 2026. 2. Any other agenda, with prior permission of Chairperson. |
|
Batliboi
|
522004 |
07-Oct-26 |
Batliboi Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/10/2026 inter alia to consider and approve 1. the variation of the terms of 692480 1% Redeemable Non-Cumulative Preference Shares of Rs. 100/- each held by Mr. Nirmal Bhogilal Promoter and Chairman of the Company so as to render the same convertible into equity shares of the Company in accordance with Section 48 of the Companies Act 2013 and the subsequent conversion thereof into equity shares;
2. the conversion of the unsecured loan of Rs. 150000000/- extended by Mr. Nirmal Bhogilal Promoter and Chairman of the Company into equity shares of the Company in accordance with Section 62(3) of the Companies Act 2013; and
3. the issue and allotment of equity shares of the Company on a preferential basis for consideration other than cash pursuant to (i) and (ii) above subject to such regulatory/statutory approvals including the approval of the shareholders of the Company as may be required.
We request you to take the above information on record |
|
Indrayani Biotec
|
526445 |
07-Oct-26 |
Indrayani Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/10/2026 inter alia to consider and approve 1. Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30 2026 along with the Limited Review Report by Statutory Auditors.
2. Proposal for the reconstitution of various Committees of the Board of Directors. |
|
Galaxy Agrico
|
531911 |
07-Oct-26 |
Galaxy Agrico Exports Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/10/2026 ,inter alia, to consider and approve 1. To consider and approve the fixation of Record Date for the purpose of sub-division / split of the existing Equity Shares of the Company having face value of ?10/- (Rupees Ten only) each into Equity Shares having face value of ?1/- (Rupee One only). 2. Any other business with the permission of Chairperson. |
|
Alstone Textiles
|
539277 |
07-Oct-26 |
Alstone Textiles (India) Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/10/2026 inter alia to consider and approve Pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations 2015 we hereby inform you that a meeting of Board of Directors of the Company will be held on Wednesday 07th October 2026 at the corporate office of the Company at
47/18 Old Rajinder Nagar Near Rajendra Place Metro Station New Delhi-110060 with respect to following:
1. To consider and approve the Unaudited (Standalone) Financial Results of the Company for the Quarter and half year ended on 30th September 2026. |
|
TAVEXIA LIFECARE
|
539519 |
07-Oct-26 |
Inter alia, to consider and discuss the following matter: 1. To further discuss and deliberate upon the matter relating to the proposed acquisition of up to 60% of the equity share capital of Meyonex Pharmaceuticals Limited, an unlisted public company having CIN: U74120MH2015PLC261024. The aforesaid matter is being considered with reference to the previous meeting of the Board of Directors of the Company held on Monday, 07th September, 2026, wherein the Board had considered and approved the proposal for acquisition of up to 60% of the equity share capital of Meyonex Pharmaceuticals Limited and authorised the designated representatives of the Company to undertake preliminary evaluation, due diligence, valuation and negotiations in relation thereto. The Board shall further discuss and deliberate upon the developments in the matter and decide the further course of action in relation to the proposed acquisition. 2. To consider and transact any other business with the permission of the Chairperson. |